Gilead Sciences’ (GILD) “Outperform” Rating Reiterated at Robert W. Baird
Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reissued by equities research analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday. They currently have a $100.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $122.00. Robert W. Baird’s target price would indicate a potential upside of 37.67% from the company’s current price.
Other research analysts have also issued reports about the company. Leerink Swann reissued a “buy” rating and set a $120.00 price target on shares of Gilead Sciences in a report on Tuesday, June 21st. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 price target on the stock. in a report on Wednesday, July 6th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $97.00 price target on the stock in a report on Monday, July 11th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $120.00 target price on shares of Gilead Sciences in a report on Wednesday, June 29th. Finally, RBC Capital Markets set a $105.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, August 11th. Ten equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $102.78.
Gilead Sciences (NASDAQ:GILD) traded up 1.03% on Tuesday, hitting $73.39. 5,554,374 shares of the stock were exchanged. The company has a market cap of $96.85 billion, a PE ratio of 6.44 and a beta of 1.10. Gilead Sciences has a 52 week low of $72.21 and a 52 week high of $111.11. The company’s 50-day moving average is $77.72 and its 200-day moving average is $84.20.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period last year, the company earned $3.15 earnings per share. On average, analysts predict that Gilead Sciences will post $11.76 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.59%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio is currently 16.56%.
In other Gilead Sciences news, insider John F. Milligan sold 70,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total value of $5,441,800.00. Following the transaction, the insider now directly owns 1,128,963 shares of the company’s stock, valued at approximately $87,765,583.62. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $80.50, for a total value of $8,050,000.00. Following the completion of the transaction, the insider now directly owns 4,119,727 shares in the company, valued at $331,638,023.50. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Van Hulzen Asset Management LLC increased its position in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 100 shares in the last quarter. Gemmer Asset Management LLC boosted its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares in the last quarter. Joel Isaacson & Co. LLC boosted its stake in Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares in the last quarter. Roble Belko & Company Inc boosted its stake in Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 301 shares in the last quarter. 78.00% of the stock is currently owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.